Abstract
BackgroundLetetresgene autoleucel (lete-cel; GSK3377794) is a first-generation (1st gen) NY-ESO-1-specific T-cell receptor (TCR) therapy with demonstrated clinical activity in solid tumors.1-2 Next-generation T-cell therapies are in development with the goal...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have